JP2011524903A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524903A5
JP2011524903A5 JP2011514598A JP2011514598A JP2011524903A5 JP 2011524903 A5 JP2011524903 A5 JP 2011524903A5 JP 2011514598 A JP2011514598 A JP 2011514598A JP 2011514598 A JP2011514598 A JP 2011514598A JP 2011524903 A5 JP2011524903 A5 JP 2011524903A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
present
compound
weight
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011514598A
Other languages
English (en)
Japanese (ja)
Other versions
JP5566380B2 (ja
JP2011524903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003602 external-priority patent/WO2009154737A1/en
Publication of JP2011524903A publication Critical patent/JP2011524903A/ja
Publication of JP2011524903A5 publication Critical patent/JP2011524903A5/ja
Application granted granted Critical
Publication of JP5566380B2 publication Critical patent/JP5566380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011514598A 2008-06-17 2009-06-16 ボロン酸エステル化合物およびその医薬組成物 Active JP5566380B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13224408P 2008-06-17 2008-06-17
US61/132,244 2008-06-17
US21149909P 2009-03-31 2009-03-31
US61/211,499 2009-03-31
PCT/US2009/003602 WO2009154737A1 (en) 2008-06-17 2009-06-16 Boronate ester compounds and pharmaceutical compositions thereof

Related Child Applications (4)

Application Number Title Priority Date Filing Date
JP2014103398A Division JP2014169317A (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103396A Division JP6110813B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103397A Division JP5926319B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103395A Division JP6010066B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物

Publications (3)

Publication Number Publication Date
JP2011524903A JP2011524903A (ja) 2011-09-08
JP2011524903A5 true JP2011524903A5 (enExample) 2012-08-02
JP5566380B2 JP5566380B2 (ja) 2014-08-06

Family

ID=41061278

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2011514598A Active JP5566380B2 (ja) 2008-06-17 2009-06-16 ボロン酸エステル化合物およびその医薬組成物
JP2014103395A Active JP6010066B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103398A Withdrawn JP2014169317A (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103397A Active JP5926319B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103396A Active JP6110813B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2017128843A Withdrawn JP2017214396A (ja) 2008-06-17 2017-06-30 ボロン酸エステル化合物およびその医薬組成物
JP2019216272A Withdrawn JP2020055829A (ja) 2008-06-17 2019-11-29 ボロン酸エステル化合物およびその医薬組成物
JP2021109909A Withdrawn JP2021165288A (ja) 2008-06-17 2021-07-01 ボロン酸エステル化合物およびその医薬組成物
JP2023145377A Withdrawn JP2023158150A (ja) 2008-06-17 2023-09-07 ボロン酸エステル化合物およびその医薬組成物
JP2025141388A Pending JP2025172854A (ja) 2008-06-17 2025-08-27 ボロン酸エステル化合物およびその医薬組成物

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2014103395A Active JP6010066B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103398A Withdrawn JP2014169317A (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103397A Active JP5926319B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2014103396A Active JP6110813B2 (ja) 2008-06-17 2014-05-19 ボロン酸エステル化合物およびその医薬組成物
JP2017128843A Withdrawn JP2017214396A (ja) 2008-06-17 2017-06-30 ボロン酸エステル化合物およびその医薬組成物
JP2019216272A Withdrawn JP2020055829A (ja) 2008-06-17 2019-11-29 ボロン酸エステル化合物およびその医薬組成物
JP2021109909A Withdrawn JP2021165288A (ja) 2008-06-17 2021-07-01 ボロン酸エステル化合物およびその医薬組成物
JP2023145377A Withdrawn JP2023158150A (ja) 2008-06-17 2023-09-07 ボロン酸エステル化合物およびその医薬組成物
JP2025141388A Pending JP2025172854A (ja) 2008-06-17 2025-08-27 ボロン酸エステル化合物およびその医薬組成物

Country Status (39)

Country Link
US (17) US20090325903A1 (enExample)
EP (6) EP2730579A1 (enExample)
JP (10) JP5566380B2 (enExample)
KR (5) KR101860743B1 (enExample)
CN (10) CN103450241A (enExample)
AR (1) AR072162A1 (enExample)
AU (1) AU2009260778B2 (enExample)
BR (4) BR122014008750A2 (enExample)
CA (2) CA2727862C (enExample)
CL (1) CL2010001475A1 (enExample)
CO (1) CO6321289A2 (enExample)
CR (3) CR11850A (enExample)
CY (1) CY1116435T1 (enExample)
DK (2) DK2730581T3 (enExample)
DO (1) DOP2010000384A (enExample)
EA (4) EA030685B1 (enExample)
EC (2) ECSP11010763A (enExample)
ES (2) ES2585114T3 (enExample)
FI (1) FI2318419T4 (enExample)
GE (2) GEP201706703B (enExample)
HK (7) HK1198254A1 (enExample)
HR (1) HRP20150592T4 (enExample)
IL (3) IL210056B (enExample)
MA (1) MA32471B1 (enExample)
MX (4) MX340186B (enExample)
MY (2) MY171021A (enExample)
NO (1) NO2017016I1 (enExample)
NZ (4) NZ624122A (enExample)
PE (5) PE20141064A1 (enExample)
PH (3) PH12015501192B1 (enExample)
PL (1) PL2318419T3 (enExample)
PT (2) PT2730581T (enExample)
RS (1) RS54020B2 (enExample)
SG (2) SG10201701524XA (enExample)
SI (1) SI2318419T2 (enExample)
TW (3) TWI498333B (enExample)
UA (1) UA115131C2 (enExample)
WO (1) WO2009154737A1 (enExample)
ZA (4) ZA201009177B (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス, インク. 酵素阻害のための化合物
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
HRP20150592T4 (hr) * 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
KR101023994B1 (ko) 2008-08-28 2011-03-28 한국생산기술연구원 디지털 밴드용 커넥터, 리셉터클 및 커넥터 조립체
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
PH12012501719A1 (en) 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
JP5933523B2 (ja) 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 1−アミノ−2−シクロプロピルエチルボロン酸の誘導体
AU2011312264B2 (en) * 2010-10-05 2015-07-02 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
MX2013015308A (es) 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2855368A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
CA2862492A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2013112598A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal caner
EP2819673B1 (en) * 2012-03-02 2016-09-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising boronic acid compounds
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
ITMI20121394A1 (it) 2012-08-06 2014-02-07 Chemi Spa Esteri di bortezomib e loro formulazioni
EP3008212A4 (en) * 2013-06-10 2017-05-24 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2015025000A1 (en) * 2013-08-23 2015-02-26 Synthon B.V. Pharmaceutical compositions comprising bortezomib
CA2925935A1 (en) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
WO2015117136A1 (en) * 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
JP2015200016A (ja) * 2014-03-31 2015-11-12 富士フイルム株式会社 水分解用光電極、水分解装置
SG10202003693RA (en) * 2014-05-20 2020-05-28 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
EP3031811A1 (en) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Malic acid esters of bortezomib
MA41505A (fr) * 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CZ2015233A3 (cs) 2015-04-03 2016-10-12 Zentiva, K.S. Způsob přípravy Ixazomib citrátu
CZ2015253A3 (cs) 2015-04-15 2016-10-26 Zentiva, K.S. Nové formy Ixazomib citrátu
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2016205790A2 (en) * 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
EP3120836A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Gebrauchsfertige bortezomib-lösung
WO2017046815A1 (en) 2015-09-16 2017-03-23 Mylan Laboratories Limited Polymorphs of ixazomib citrate and processes for the preparation thereof
CN106608883A (zh) * 2015-10-21 2017-05-03 北京大学 蛋白酶体抑制剂mln9708的合成方法
EP3370729B1 (en) 2015-11-04 2023-09-27 Takeda Pharmaceutical Company Limited Methods for the identification, evaluation and treatment of patients having multiple myeloma
CN106986884A (zh) * 2016-01-20 2017-07-28 成都贝斯凯瑞生物科技有限公司 一种高效的高纯度含硼化合物制备方法
CN105622658B (zh) * 2016-03-18 2018-06-19 中国药科大学 非肽类蛋白酶体抑制剂、其药物组合物、制备方法和应用
WO2017163190A1 (en) * 2016-03-23 2017-09-28 Dr. Reddy’S Laboratories Limited Amorphous ixazomib citrate and solid dispersion thereof
CN107224569A (zh) * 2016-03-26 2017-10-03 复旦大学 一种硼替佐米水溶性药用组合物及其制备方法和用途
CZ2016204A3 (cs) 2016-04-08 2017-11-01 Zentiva, K.S. Formulace Ixazomib citrátu formy 3
EP3798224B1 (en) 2016-06-21 2025-03-19 Assia Chemical Industries LTD Solid state forms of ixazomib citrate
EP3476850B1 (en) 2016-07-25 2024-12-11 Shenzhen TargetRx, Inc. Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
MA45862A (fr) * 2016-08-04 2021-05-05 Millennium Pharm Inc Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30
WO2018133661A1 (zh) * 2017-01-23 2018-07-26 成都奥璟生物科技有限公司 一种新的硼酸衍生物及其药物组合物
EP3589659B1 (en) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinations for use in the treatment of cancer
WO2018158697A1 (en) 2017-03-03 2018-09-07 Fresenius Kabi Oncology Limited A process for the preparation of ixazomib citrate
WO2018173071A1 (en) * 2017-03-20 2018-09-27 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of ixazomib citrate and its process for preparation thereof
CN106916177B (zh) * 2017-03-23 2019-04-23 南京陵瑞医药科技有限公司 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
CN108794520B (zh) * 2017-05-02 2020-07-24 北京大学 包括埃沙佐米在内的硼酸柠檬酸酯类化合物的合成方法
CN109305980B (zh) * 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
CA3073611A1 (en) 2017-08-24 2019-02-28 Merck Patent Gmbh Boronic acid derivatives
US20200199159A1 (en) 2017-08-25 2020-06-25 Synthon B.V. Process for making ixazomib or intermediates therefor
CA3074247A1 (en) * 2017-09-02 2019-03-07 Sun Pharmaceutical Industries Limited Process for the preparation of ixazomib citrate
JP2020533382A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 癌の組合せ治療
CN113603713B (zh) * 2017-12-05 2024-11-12 深圳市塔吉瑞生物医药有限公司 一种取代的硼酸酯化合物的制备方法及其晶型
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10118937B1 (en) 2018-01-03 2018-11-06 Scinopharm Taiwan, Ltd. Process for preparing ixazomib citrate and intermediates therefor
CN110041353A (zh) * 2018-01-16 2019-07-23 成都译山生物科技有限公司 一种新的硼酸水杨酸酯类衍生物及其药物组合物
US12054500B2 (en) 2018-03-05 2024-08-06 Arcus Biosciences, Inc. Arginase inhibitors
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
IL280376B2 (en) 2018-07-26 2024-08-01 Merck Patent Gmbh Boronic acid derivatives, their preparation and pharmaceutical compositions containing them
BR112021001963B1 (pt) * 2018-08-02 2024-02-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Compostos de borato de um derivado de azetidina, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para prevenção ou tratamento de mieloma múltiplo
CN110903310B (zh) * 2018-09-14 2022-11-22 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
WO2020102646A2 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
CN110357787A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 依沙佐米合成工艺研究
CA3158188A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts
EP4547676A1 (en) 2022-06-30 2025-05-07 Principia Biopharma Inc. Cyclic boronic esters and their uses
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN116396312A (zh) * 2022-12-26 2023-07-07 重庆迈德凯医药有限公司 一种枸橼酸艾沙佐米的制备方法
WO2025117822A1 (en) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs
CN117964650B (zh) * 2024-03-28 2024-06-07 成都硕德药业有限公司 一种枸橼酸伊沙佐米的制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449082A (en) * 1891-03-24 milbeadt
US2160413A (en) 1935-04-16 1939-05-30 Schering Ag Polyiodo derivatives of acylamino acids and their salts and a method of making the same
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
JPS6197352A (ja) * 1984-10-17 1986-05-15 Dai Ichi Kogyo Seiyaku Co Ltd 安定性に優れた組成物
JPS6233170A (ja) 1985-08-07 1987-02-13 Tokuyama Soda Co Ltd 環状ポリエ−テル化合物
JPH0813759B2 (ja) 1986-09-01 1996-02-14 富士写真フイルム株式会社 アルコキシベンゼン誘導体の製造方法
JP2512303B2 (ja) 1987-03-20 1996-07-03 呉羽化学工業株式会社 2−オキサゾリン−4,5−ジオンのフエニルヒドラゾン誘導体
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
MX9206628A (es) * 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
US5492900A (en) * 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US5935944A (en) * 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
JP3403009B2 (ja) * 1996-07-12 2003-05-06 キヤノン株式会社 可動部材の変位と気泡成長を伴う液体吐出方法、該吐出方法に用いられる液体吐出ヘッド、ヘッドカートリッジ及びこれらを用いた液体吐出装置
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
ATE240113T1 (de) 1997-02-15 2003-05-15 Millennium Pharm Inc Behandlung von infarkten durch inhibierung von nf-kappab
EP1017398A1 (en) 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
JP2002508321A (ja) 1997-12-16 2002-03-19 セフアロン・インコーポレーテツド 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
AU6229699A (en) 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
US6121149A (en) * 1999-04-22 2000-09-19 Advanced Micro Devices, Inc. Optimized trench/via profile for damascene filling
KR100307027B1 (ko) 1999-06-17 2001-11-01 서평원 액정 표시장치 및 이것을 이용한 이동 통신 단말기의 표시장치
WO2001002601A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
SE0100714D0 (sv) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002145848A (ja) * 2000-11-10 2002-05-22 Kyorin Pharmaceut Co Ltd アルケニルアミノ酸誘導体及びその製造法
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
PT3078667T (pt) 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
CA2446282A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
DE10131283A1 (de) 2001-06-28 2003-01-09 Philips Corp Intellectual Pty Phased Array Antenne
WO2003033506A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Aminoborane acid derivative and proteasome inhibitory drug containing the same
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
AU2003263343A1 (en) 2002-09-09 2004-03-29 Trigen Limited Boronic acid salts ant their use in the treatment of thromobis
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
RS53259B (sr) * 2004-03-30 2014-08-29 Millennium Pharmaceuticals Inc. Sinteza bortezomiba
BRPI0510802A (pt) 2004-05-10 2007-11-06 Proteolix Inc compostos para inibição de enzima
WO2006008660A2 (en) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN101120006A (zh) * 2005-02-11 2008-02-06 赛福伦公司 蛋白酶体抑制剂及其使用方法
JP2008539273A (ja) 2005-04-29 2008-11-13 コーザン バイオサイエンシス インコーポレイテッド 17−aag又は17−ag又はどちらかのプロドラッグをプロテアソーム阻害剤と組み合わせて使用する多発性骨髄腫の治療方法
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
AU2006322094A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
JP2009524681A (ja) 2006-01-27 2009-07-02 フェノミックス コーポレーション C型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
ES2458615T3 (es) 2006-02-03 2014-05-06 Taisho Pharmaceutical Co., Ltd. Derivado de triazol
CL2007002499A1 (es) * 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
EP2178888B1 (en) 2007-08-06 2012-07-04 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) * 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
ITMI20072397A1 (it) 2007-12-20 2009-06-21 Gambro Lundia Ab Apparecchiatura medicale per il trattamento extracorporeo
HRP20150592T4 (hr) * 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
JP5933523B2 (ja) 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 1−アミノ−2−シクロプロピルエチルボロン酸の誘導体
PT2702706E (pt) 2011-04-29 2015-04-08 Ericsson Telefon Ab L M Controlo descentralizado de redução de interferência num sistema de comunicação sem fios
JP5724951B2 (ja) 2012-06-11 2015-05-27 日立金属株式会社 ネットワーク管理装置
JP6357023B2 (ja) 2014-06-06 2018-07-11 任天堂株式会社 情報処理プログラム、情報処理装置、情報処理装置の制御方法および情報処理システム

Similar Documents

Publication Publication Date Title
HRP20150592T1 (hr) Organoborni esterski spojevi i njihove farmaceutske kompozicije
JP2010090149A5 (enExample)
KR102150383B1 (ko) 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법
JP7137850B2 (ja) バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
JP2018035160A5 (enExample)
JP2008525445A5 (enExample)
JP2012502037A5 (enExample)
RU2013119966A (ru) Композиция, улучшающая растворимость плохорастворимого лекарственного препарата
JP2009521269A5 (enExample)
JP2011046708A5 (enExample)
CN102793685B (zh) 含有普瑞巴林的口服胶囊及其制备方法
JP2012510985A5 (enExample)
CN103228618A (zh) 新化合物及其医药用途
JP2006500367A (ja) ブチルフタリドとシクロデキストリンまたはその誘導体との包接複合体、それらの調製のためのプロセスおよびその使用
JP2009040767A5 (enExample)
CN102225913B (zh) 大黄酸衍生物以及它们的治疗用途
JP2009502777A5 (enExample)
RU2593260C2 (ru) Производное бутилфталида, способ его получения и применение
RU2004124840A (ru) Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений
JP5461084B2 (ja) 崩壊遅延が抑制されたパロキセチン塩酸塩水和物の経口投与用医薬組成物
CN104083383A (zh) 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗急性肾衰药物中的应用
JP2013536823A5 (enExample)
JP2015524469A5 (enExample)
JP2008503574A5 (enExample)
WO2017024953A1 (zh) 尼莫地平水溶性衍生物及其制备方法和应用